Seres Therapeutics, Inc.
NASDAQ:MCRBBiotechnology
Healthcare
$5.28 +1.70%
+$0.11 today
- Market cap
- $51.13M
- Beta
- 0.11
- P/E (TTM)
- -1.3
- EPS (TTM)
- -$4.89
52W Low $5.31High $29.98
Volume 0.04M
Average 0.06M
Income Statement
Follow revenue through to earnings.
Revenue
$789,000.00
FY 2025 · Annual
Operating Income
-$93.97M
FY 2025 · Annual
Net Income
$5.70M
FY 2025 · Annual
Income Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 144.93M | 0 | 0 | 0 | 789K |
| Cost of Revenue | 0 | 0 | 19.34M | 3.53M | 4.13M |
| Gross Profit | 144.93M | 0 | (19.34M) | (3.53M) | (3.34M) |
| Gross Margin | 100.0% | — | — | — | -423.8% |
| Research & Development | 141.89M | 109.65M | 117.6M | 64.6M | 49.06M |
| Selling, General & Admin | 69.26M | 70.26M | 77.5M | 53.18M | 39.16M |
| Operating Expenses | 209.42M | 179.91M | 175.76M | 117.78M | 90.63M |
| Depreciation & Amortization | 5.95M | 6.63M | 6.24M | 5.47M | 4.13M |
| EBITDA | (56.72M) | (170.93M) | (181.42M) | (120.3M) | 9.83M |
| EBITDA Margin | -39.1% | — | — | — | 1245.8% |
| Operating Income | (64.49M) | (179.91M) | (195.1M) | (121.32M) | (93.97M) |
| Operating Margin | -44.5% | — | — | — | -11910.1% |
| Interest Income | 2.87M | 3.06M | 7.3M | 3.97M | 2.23M |
| Interest Expense | 2.91M | 6.02M | 13.18M | 0 | 0 |
| Other Income / Expenses | (1.09M) | (3.67M) | 4.97M | (4.46M) | 99.67M |
| Income Before Tax | (65.58M) | (183.58M) | (190.13M) | (125.77M) | 5.7M |
| Pre-Tax Margin | -45.2% | — | — | — | 721.9% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (65.58M) | (250.16M) | (113.72M) | (146.57M) | 5.7M |
| Net Margin | -45.2% | — | — | — | 721.9% |
| EPS (Basic) | (14.30) | (46.29) | (17.77) | (18.86) | 0.64 |
| EPS (Diluted) | (14.30) | (46.29) | (17.77) | (18.86) | 0.64 |
| 4.59M | 5.4M | 6.4M | 7.77M | 8.86M | |
| 4.59M | 5.4M | 6.4M | 7.77M | 8.87M |
MCRB Earnings Waterfall · TTM
NASDAQ:MCRB · Revenue to Net Income
Key Ratios
EPS$-5.17
Gross Margin-142.6%
Net Margin-1681.5%
P/E Ratio0.2
P/S Ratio254.6
Analysis
$1.1M of revenue converted into -$46.9M of net income for the selected period. Gross margin is -142.6% and net margin is -1681.5%, showing how much revenue survives after costs and taxes. EPS is $-5.17, tying the income statement back to per-share earnings.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| EFFECT | EFFECT filing | Aug 21, 2026 | |
| 4 | Statement of changes in beneficial ownership | Aug 18, 2026 | |
| 4 | Statement of changes in beneficial ownership | Aug 18, 2026 | |
| 4 | Statement of changes in beneficial ownership | Aug 18, 2026 | |
| 4 | Statement of changes in beneficial ownership | Aug 18, 2026 |
How much revenue does MCRB generate?
Seres Therapeutics, Inc. (MCRB) reported $789,000.00 of revenue in fiscal 2025.
Is MCRB profitable?
Seres Therapeutics, Inc. (MCRB) reported $5.70M of net income, with a net margin of 721.9%.
Continue the stock analysis
Jump to another research area for this company.